Here's Why Vertex Pharmaceuticals Is Flying High Today

In response to a report of upbeat clinical data from two phase 3 trials, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) rose by 23% as of 11:15 a.m. EDT on Wednesday.Image source: Getty Images.Vertex announced results from its phase 3 EVOLVE and EXPAND studies. Both of these trials were designed to test the efficacy and safety of a drug that combines Vertex's next-generation cystic fibrosis (CF) treatment tezacaftor with its already approved CF drug ivacaftor, which is marketed as Kalydeco. Continue reading

Topics:  vertex pharmaceuticals nasdaq   vrtx    images   evolve   expand   vertex   kalydeco   cf   drug   phase   trials   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News